CC BY-NC-ND 4.0 · Horm Metab Res 2022; 54(10): 677-685
DOI: 10.1055/a-1909-1922
Original Article: Endocrine Care
Jing Zhu‡
1
Department of Endocrinology, Third Affiliated Hospital of Soochow
University, Changzhou, China
,
Shuai Jiang‡
2
Department of Emergency Medicine, Zhejiang University School of
Medicine First Affiliated Hospital, Hangzhou, China
3
Key Laboratory for Diagnosis and Treatment of Aging and Physic-chemical
Injury Diseases of Zhejiang Province, Hangzhou, China
,
Xiaohong Jiang
1
Department of Endocrinology, Third Affiliated Hospital of Soochow
University, Changzhou, China
,
Kaiming Luo
1
Department of Endocrinology, Third Affiliated Hospital of Soochow
University, Changzhou, China
,
Xiaolin Huang
1
Department of Endocrinology, Third Affiliated Hospital of Soochow
University, Changzhou, China
,
Fei Hua
1
Department of Endocrinology, Third Affiliated Hospital of Soochow
University, Changzhou, China
› Author Affiliations
Funding
This study was funded by Changzhou Health Commission Young
Talents Project (QN202018), Natural Science Foundation of China
(81900768), and General Project of Maternal and Child Health Research
Project of Jiangsu Province (F201803).
› Further Information
Also available at
Permissions and Reprints
Abstract
Lipocalin-2 (LCN2) is becoming recognized as a pleiotropic mediator of metabolic
disorders. However, the relationship between LCN2 and gestational diabetes
mellitus (GDM) is not well understood. We performed a systematic review and
meta-analysis to explore it. A systematic search of Cochrane Library, PubMed,
Embase, Scopus, Web of Science, Chinese National Knowledge Infrastructure, and
Wan-fang Database was done for relevant articles published up to September 29,
2021. Standardized mean difference (SMD) with 95% confidence intervals
(CI) was calculated to explore the association of LCN2 levels with GDM using
Revman 5.3 and Stata 15.1. Fifteen case-control studies were included in this
meta-analysis. The patients with GDM had significantly higher levels of blood
LCN2 than parturients with normal glucose tolerance (SMD=3.41,
95% CI=2.24 to 4.58). Meta-regression and subgroup analysis were
conducted to investigate the source of heterogeneity. Likely sources of
heterogeneity were age and testing methods. This study found that GDM showed
higher blood LCN2 levels than controls. However, caution is warranted on the
interpretation of these findings. Standardized LCN2 measurement methods and
longitudinal studies are required to disentangle and better understand the
relationships observed.
Key words
lipocalin-2 -
gestational diabetes mellitus -
meta-analysis -
insulin resistance -
adipokines
Publication History
Received: 26 January 2022
Accepted after revision: 18 July 2022
Article published online:
07 October 2022
© 2022. The Author(s). This is an open access article published by
Thieme under the terms of the Creative Commons
Attribution-NonDerivative-NonCommercial-License, permitting copying and
reproduction so long as the original work is given appropriate credit. Contents
may not be used for commercial purposes, or adapted, remixed, transformed or
built upon.
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Metzger BE,
Gabbe SG,
Persson B.
et al.
International association of diabetes and pregnancy study groups recommendations
on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-682
2
Ferrara A.
Increasing prevalence of gestational diabetes mellitus: a public health
perspective. Diabetes Care 2007; 30: S141-S146
3
Rodrigo N,
Glastras SJ.
The emerging role of biomarkers in the diagnosis of gestational diabetes
mellitus. J Clin Med 2018; 7: 120
4
Yin X,
Huo Y,
Liu L.
et al.
Serum levels and placental expression of NGAL in gestational diabetes
mellitus. Int J Endocrinol 2020; 8760563
5
McIntyre HD,
Catalano P,
Zhang C.
et al.
Gestational diabetes mellitus. Nat Rev Dis Primers 2019; 5: 47 DOI:
10.1038/s41572-019-0098-8.
6
Nguyen-Ngo C,
Jayabalan N,
Salomon C.
et al.
Molecular pathways disrupted by gestational diabetes mellitus. J Mol Endocrinol 2019; 63: R51-R72
7
de Gennaro G,
Palla G,
Battini L.
et al.
The role of adipokines in the pathogenesis of gestational diabetes mellitus. Gynecol Endocrinol 2019; 35: 737-751
8
Gutaj P,
Sibiak R,
Jankowski M.
et al.
The role of the adipokines in the most common gestational complications. Int J Mol Sci 2020; 21: 9408
9
Bhusal A,
Rahman MH,
Lee WH.
et al.
Paradoxical role of lipocalin-2 in metabolic disorders and neurological
complications. Biochem Pharmacol 2019; 169: 113626
10
Xiao X,
Yeoh BS,
Vijay-Kumar M.
Lipocalin 2: an emerging player in iron homeostasis and inflammation. Annu Rev Nutr 2017; 37: 103-130
11
Kjeldsen L,
Bainton DF,
Sengeløv H.
et al.
Identification of neutrophil gelatinase-associated lipocalin as a novel matrix
protein of specific granules in human neutrophils. Blood 1994; 83: 799-807
12
Lou Y,
Wu C,
Wu M.
et al.
The changes of neutrophil gelatinase-associated lipocalin in plasma and its
expression in adipose tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract 2014; 104: 136-142
13
Bhusal A,
Lee WH,
Suk K.
Lipocalin-2 in diabetic complications of the nervous system: physiology,
pathology, and beyond. Front Physiol 2021; 12: 638112
14
Cesur S,
Yucel A,
Noyan V.
et al.
Plasma lipocalin-2 levels in pregnancy. Acta Obstet Gynecol Scand 2012; 91: 112-116
15
D’Anna R,
Baviera G,
Corrado F.
et al.
First trimester serum neutrophil gelatinase-associated lipocalin in gestational
diabetes. Diabet Med 2009; 26: 1293-1295
16
Ravnsborg T,
Andersen LLT,
Trabjerg ND.
et al.
First-trimester multimarker prediction of gestational diabetes mellitus using
targeted mass spectrometry. Diabetologia 2016; 59: 970-979
17
Saucedo R,
Valencia J,
Moreno-Gonzalez LE.
et al.
Maternal serum adipokines and inflammatory markers at late gestation and newborn
weight in mothers with and without gestational diabetes mellitus. Ginekol Polska 2021; DOI:
10.5603/GP.a2021.0083.
18
Komici K,
Dello Iacono A,
De Luca A.
et al.
Adiponectin and sarcopenia: a systematic review with meta-analysis. Front Endocrinol (Lausanne) 2021; 12: 576619
19
Shi J,
Luo D,
Weng H.
et al.
Optimally estimating the sample standard deviation from the five-number
summary. Res Synth Meth 2020; 11: 641-654
20
Luo D,
Wan X,
Liu J.
et al.
Optimally estimating the sample mean from the sample size, median, mid-range,
and/or mid-quartile range. Stat Methods Med Res 2018; 27: 1785-1805
21
Wan X,
Wang W,
Liu J.
et al.
Estimating the sample mean and standard deviation from the sample size, median,
range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
22
Lo CK,
Mertz D,
Loeb M.
Newcastle-Ottawa Scale: comparing reviewers’ to authors’
assessments. BMC Med Res Methodol 2014; 14: 45
23
Ma Q,
Chen Y.
Study on the expression of serum level of NGAL and its relationship with
gestational diabetes in early pregnancy. J Clin Exp Med (Chinese) 2015; DOI:
10.3969/j.issn.1671-4695.2015.011.022. 930-933
24
Mierzynski R,
Poniedzialek-Czajkowska E,
Dluski D.
et al.
The potential role of chemerin, lipocalin 2, and apelin in the diagnosis and
pathophysiology of gestational diabetes mellitus. J Diabetes Res 2021; 5547228 DOI:
10.1155/2021/5547228. eCollection 2021.
25
Duan D,
Niu J,
Zhu B.
et al.
Serum level of neutrophii gelatinase-assoeiated lipocalin in preeclampsia with
gestatiunal diabetes mellitus. Chin J Perinat Med (Chinese) 2012; 15: 222-227
26
Guo J.
Relationship between neutrophil gelatinase-associated lipocalin and insulin
resistance in diabetic gravida. Modern Prevent Med (Chinese) 2014; 41: 1599-1601 1604
27
Guo L,
Zhang C,
Guo Y.
Changes and significance of serum LCN-2 and AOPP levels in patients with
gestational diabetes mellitus complicated with preeclampsia. Shandong Med J (Chinese) 2019; 59: 12-15
28
Kang Y.
The value of adiponectin, resistin and lipocalin-2 tests in early diagnosis of
gestational diabetes mellitus. Label Immun. Clin Med (Chinese) 2018; 25: 1192-1195
29
Wang F,
Ye L,
Yang L.
et al.
Changes of serum neutrophic gelatinase-associated lipocalin in gestational
diabetes mellitus. Chin J Microcirculat (Chinese) 2013; 23: 19-21
30
He X,
Gu D,
Chen S.
et al.
Clinical significanle of NGAL in women with gestational diabetes mellitus. China Med Pharm (Chinese) 2018; 8: 35-38
31
Plows JF,
Stanley JL,
Baker PN.
et al.
The pathophysiology of gestational diabetes mellitus. Int J Mol Sci 2018; 19: 3342
32
Zhang C,
Liu S,
Solomon CG.
et al.
Dietary fiber intake, dietary glycemic load, and the risk for gestational
diabetes mellitus. Diabetes Care 2006; 29: 2223-2230
33
Binder AM,
LaRocca J,
Lesseur C.
et al.
Epigenome-wide and transcriptome-wide analyses reveal gestational diabetes is
associated with alterations in the human leukocyte antigen complex. Clin Epigenet 2015; 7: 79
34
De la Chesnaye E,
Manuel-Apolinar L,
Oviedo-de Anda N.
et al.
[Gender differences in lipocalin 2 plasmatic levels are correlated with age and
the triglyceride/high-density lipoprotein ratio in healthy
individuals]. Gac Med Mex 2016; 152: 612-617
35
Wu G,
Li H,
Zhou M.
et al.
Mechanism and clinical evidence of lipocalin-2 and adipocyte fatty acid-binding
protein linking obesity and atherosclerosis. Diabetes Metab Res Rev 2014; 30: 447-456
36
Abella V,
Scotece M,
Conde J.
et al.
The potential of lipocalin-2/NGAL as biomarker for inflammatory and
metabolic diseases. Biomarkers 2015; 20: 565-571
37
Wang Y,
Lam KS,
Kraegen EW.
et al.
Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin
resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41
38
Yan QW,
Yang Q,
Mody N.
et al.
The adipokine lipocalin 2 is regulated by obesity and promotes insulin
resistance. Diabetes 2007; 56: 2533-2540
39
Sun WX,
Lou K,
Chen LJ.
et al.
Lipocalin-2: a role in hepatic gluconeogenesis via AMP-activated protein kinase
(AMPK). J Endocrinol Invest 2021; 44: 1753-1765
40
Law IK,
Xu A,
Lam KS.
et al.
Lipocalin-2 deficiency attenuates insulin resistance associated with aging and
obesity. Diabetes 2010; 59: 872-882
41
Chan YK,
Sung HK,
Jahng JW.
et al.
Lipocalin-2 inhibits autophagy and induces insulin resistance in H9c2 cells. Mol Cell Endocrinol 2016; 430: 68-76
42
Chella Krishnan K,
Sabir S,
Shum M.
et al.
Sex-specific metabolic functions of adipose lipocalin-2. Mol Metab 2019; 30: 30-47
43
Jaberi SA,
Cohen A,
D’Souza C.
et al.
Lipocalin-2: structure, function, distribution and role in metabolic
disorders. Biomed Pharmacother 2021; 142: 112002
44
Kamble PG,
Pereira MJ,
Sidibeh CO.
et al.
Lipocalin 2 produces insulin resistance and can be upregulated by
glucocorticoids in human adipose tissue. Mol Cell Endocrinol 2016; 427: 124-132
45
Auguet T,
Quintero Y,
Terra X.
et al.
Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive
relationship with proinflammatory cytokines. Obesity (Silver Spring) 2011; 19: 2295-2300
46
Catalán V,
Gómez-Ambrosi J,
Rodríguez A.
et al.
Increased adipose tissue expression of lipocalin-2 in obesity is related to
inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities
in humans. J Mol Med (Berl) 2009; 87: 803-813
47
Liu JT,
Song E,
Xu A.
et al.
Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary
obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012; 165: 520-531
48
Li D,
Yan Sun W,
Fu B.
et al.
Lipocalin-2 – the myth of its expression and function. Basic Clin Pharmacol Toxicol 2020; 127: 142-151
49
Clerico A,
Galli C,
Fortunato A.
et al.
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney
injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012; 50: 1505-1517
50
Valsamakis G,
Kumar S,
Creatsas G.
et al.
The effects of adipose tissue and adipocytokines in human pregnancy. Ann N Y Acad Sci 2010; 1205: 76-81
51
Deis JA,
Guo H,
Wu Y.
et al.
Adipose lipocalin 2 overexpression protects against age-related decline in
thermogenic function of adipose tissue and metabolic deterioration. Mol Metab 2019; 24: 18-29
52
Tan BK,
Adya R,
Shan X.
et al.
Ex vivo and in vivo regulation of lipocalin-2, a novel adipokine, by
insulin. Diabetes Care 2009; 32: 129-131
53
Moreno-Navarrete JM,
Manco M,
Ibáñez J.
et al.
Metabolic endotoxemia and saturated fat contribute to circulating NGAL
concentrations in subjects with insulin resistance. Int J Obes (Lond) 2010; 34: 240-249
54
Stroup DF,
Berlin JA,
Morton SC.
et al.
Meta-analysis of observational studies in epidemiology: a proposal for
reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE)
group. JAMA 2000; 283: 2008-2012
留言 (0)